An infant born to an HIV-positive mother was delivered by cesarean section, started on prophylaxis, and was not breastfed. Which is the correct management approach?

An infant born to an HIV-positive mother was delivered by cesarean section, started on prophylaxis, and was not breastfed. Which is the correct management approach?

• A. Discontinue cART after 4 weeks of age.
• B. Consult with a pediatric HIV specialist.
• C. Obtain a CD4+ cell count and HIV RNA levels.
• D. Reinforce the need to give cART for life.

Answer: (B)

Managing a newborn exposed to HIV, even when birth occurred by cesarean, when prophylaxis is started and breastfeeding is avoided, requires specialized, ongoing guidance. The best next step is to involve a pediatric HIV specialist who can tailor and coordinate the entire plan. This specialist will determine the exact testing schedule (for example, HIV nucleic acid testing such as DNA PCR or HIV RNA testing at birth and at subsequent intervals), interpret results correctly in the infant environment where maternal antibodies can complic serology, and decide if and when antiretroviral therapy should be initiated beyond prophylaxis if infection is confirmed. They also oversee the duration and choice of prophylaxis and arrange long-term follow-up and treatment if infection develops. Discontinuing antiretroviral therapy after a fixed period is not appropriate without confirming infection status and guidance from a specialist. Routine CD4 counts and HIV RNA levels are part of monitoring and testing, but in isolation they don’t replace the need for specialized perinatal HIV management and a clear testing/treatment plan. Treating all exposed infants with life-long cART regardless of infection status is not indicated; therapy is started if infection is confirmed, under expert supervision.

Managing a newborn exposed to HIV, even when birth occurred by cesarean, when prophylaxis is started and breastfeeding is avoided, requires specialized, ongoing guidance. The best next step is to involve a pediatric HIV specialist who can tailor and coordinate the entire plan. This specialist will determine the exact testing schedule (for example, HIV nucleic acid testing such as DNA PCR or HIV RNA testing at birth and at subsequent intervals), interpret results correctly in the infant environment where maternal antibodies can complic serology, and decide if and when antiretroviral therapy should be initiated beyond prophylaxis if infection is confirmed. They also oversee the duration and choice of prophylaxis and arrange long-term follow-up and treatment if infection develops.

Discontinuing antiretroviral therapy after a fixed period is not appropriate without confirming infection status and guidance from a specialist. Routine CD4 counts and HIV RNA levels are part of monitoring and testing, but in isolation they don’t replace the need for specialized perinatal HIV management and a clear testing/treatment plan. Treating all exposed infants with life-long cART regardless of infection status is not indicated; therapy is started if infection is confirmed, under expert supervision.